Baxter to Make Therapy More Convenient

Baxter International has announced the availability of data supporting further progress in efforts to make antibody therapy more convenient for patients with primary immunodeficiency (PID). It includes ways to give patients more options of where, how often and when they receive treatment.

The method involves application under the skin using an enzyme that can help deliver and disperse the antibodies into the body at the appropriate dose. This is an investigational study that the company has undertaken to develop a subcutaneous mode of administration of Intravenous Immune Globulin (IVIG) therapy to patients.